Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | AGXT | P21549 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1020554 | 0.87 | CHRM2 (0.48) | AOC3HTR6LTA4HDHFRLTB4R | |
| SCHEMBL1020111 | 0.85 | NOS2 (0.44) | TAAR1AOC3HTR6LTA4HALDH1A1 | |
| SCHEMBL1020890 | 0.84 | TAAR1 (0.41) | TAAR1HTR6LTA4HIDO1ALDH1A1 | |
| SCHEMBL1019214 | 0.83 | HTR6 (0.41) | TAAR1HTR6IDO1AGXTALDH1A1 | |
| SCHEMBL1022394 | 0.82 | CARM1 (0.41) | TAAR1AOC3HTR6LTB4RKDM4E | |
| SCHEMBL1020526 | 0.80 | BMP1 (0.41) | ALDH1A1LMNAMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL1020465 | 0.80 | CYP19A1 (0.47) | ALDH1A1LMNAMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL1020707 | 0.78 | MAPT (0.43) | HTR6KDM4EALDH1A1LMNAGBA1 | |
| SCHEMBL14736517 | 0.77 | LTA4H (0.54) | TAAR1AOC3HTR6LTA4HDHFR | |
| SCHEMBL13820352 | 0.77 | HTR6 (0.36) | HTR6LTA4HDHFRLTB4RHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960556-B2 | Thiadiazole derivatives for the treatment of neuro-degenerative diseases | NV REMYND (BE) | 2011-06-14 | — | — | US | disclosed |
| US-7960556-B2 | Thiadiazole derivatives for the treatment of neuro-degenerative diseases | NV REMYND (BE) | 2011-06-14 | — | — | US | disclosed |
| US-7960556-B2 | Thiadiazole derivatives for the treatment of neuro-degenerative diseases | NV REMYND (BE) | 2011-06-14 | — | — | US | disclosed |
| EP-2094677-B1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | REMYND NV (BE) | 2011-01-12 | — | — | EP | disclosed |
| EP-2094677-B1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | REMYND NV (BE) | 2011-01-12 | — | — | EP | disclosed |
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-06-10 | — | — | US | disclosed |
| WO-2008061781-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | SNCA, PARK7, PRNP | TAAR1 2621/4885AOC3 810/4885HTR6 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.